Cadila Healthcare Limited
- Research & Development of New Chemical Entities (NCE)
- Manufacturing, marketing and selling of finished dosage human formulations
- Generics / Branded Generics
- Specialty Formulations
- Biosimilars
- Vaccines
- Active pharmaceutical ingredients (APIs)
- Animal healthcare products
- Consumer wellness products via its subsidiary Zydus Wellness Limited
New Chemical Entity (NCE) research is characterized by large expenditures, long timelines especially in the late phases of clinical
trials, increasingly stringent regulatory environment and the commercialization related uncertainties. The company is working on cutting edge
technologies in different scientific disciplines to discover novel therapeutic agents. It has the capabilities to conduct drug discovery and
development from concept to Investigational New Drug (IND) enabling pre-clinical and clinical studies. Focused areas of NCE research include
cardio-metabolic disorders, inflammation, pain, oncology and infectious diseases.
Biosimilar Drugs vs Generic Drugs
Biosimilar drugs are often confused with generic drugs. Both are marketed as cheaper versions of costly name-brand drugs. Both are available when drug companies’ exclusive patents on expensive new drugs expire. While generic drugs are identical to the original in chemical composition, biosimilar drugs are "highly similar," but close enough in duplication to accomplish the same therapeutic and clinical result. Another key difference is that generics are copies of synthetic drugs, while biosimilars are modeled after drugs that use living organisms as important ingredients.
Biosimilar drugs are often confused with generic drugs. Both are marketed as cheaper versions of costly name-brand drugs. Both are available when drug companies’ exclusive patents on expensive new drugs expire. While generic drugs are identical to the original in chemical composition, biosimilar drugs are "highly similar," but close enough in duplication to accomplish the same therapeutic and clinical result. Another key difference is that generics are copies of synthetic drugs, while biosimilars are modeled after drugs that use living organisms as important ingredients.
“ Branded drugs are either synthetic, meaning they're made from a chemical process, or biological, meaning they're made from living sources. Synthetic branded drugs can be exactly replicated into more affordable generic versions, but because biologics involve large, complex molecules, they cannot. That's where biosimilars come into play,” says Jamie Joy, PharmD.
Generics vs Branded Generics
Ordinary generic drugs are usually known by their chemical name whereas branded generics, however, are given names to drive recognition and promote consumer loyalty. An example of a generic drug, one used for diabetes, is metformin. A brand name for metformin is Glucophage. (Brand names are usually capitalized while generic names are not.)
Specialty Formulation
The process of preparing a drug in a particular way or in a specific form, such as a tablet, capsule, linctus, ointment or one of the various form of injection.
Vaccines
A substance used to stimulate the production of antibodies and provide immunity against one or several diseases, prepared from the causative agent of a disease, its products, or a synthetic substitute, treated to act as an antigen without inducing the disease.
Active pharmaceutical ingredients (APIs)
All drugs are made up of two core components—the API, which is the central ingredient, and the excipient, the substances other than the drug that help deliver the medication to your system. Excipients are chemically inactive substances, such as lactose or mineral oil in the pill. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.
Animal Healthcare Products
The company holds leadership positions in the antimicrobials, vitamin injections, anti-mastitis, corticosteroids, Hormones and intra-mammary segments has a strong presence in Poultry vaccines, Antibiotic growth promoters, Anti-coccidials, Nutritionals and others.
The growth of the industry will be driven by the growing and ageing population in the key markets. In addition to this, improvement in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide are also driving the growth of global pharmaceuticals industry. Pharmaceutical companies across the globe are increasingly focusing on rare and specialty diseases market and innovations in these areas have attracted the investments from even companies from sectors other than pharmaceuticals, driving the growth of global pharma industry.
NSE:CADILAHC
Comments
Post a Comment